Single-dose gene therapy, betibeglogene autotemcel, may represent a cure for most with beta-thalassemia, but it costs a record-high $2.8 million. Details on how coverage will work remain murky
MedCity News
Innovative payment models to support cell and gene therapies on the rise (video)
As precision medicine gains steam, the question arises: how can reimbursement models evolve to support these often costly therapies and ensure patient access is not blocked? Drugmakers and payers are working together to find some answers.
Shares1
As the precision medicine field evolves and the science behind personalized therapies for complex conditions surges ahead, reimbursement models are racing to catch up. Precision medicine treatments, like cell and gene therapies, tend to have high price tags and novel delivery mechanisms. This makes creating effective payment models for these therapies a challenge, but drug developers and payers are working together to create out-of-the-box solutions.